Since 2019, the landscape for first-line treatment of advanced RCC has evolved. Previously, first-line therapy included immunotherapy (IO) or targeted therapy with tyrosine kinase inhibitors (TKIs) based on the patient’s risk score, favorable versus unfavorable. Since then, several IO/TKI combination regimens have been evaluated in this setting. Based on available randomized controlled trials, there are now three regimens that hold an FDA approval and a preferred, category 1 recommendation per the NCCN guidelines. As part of this presentation, there will be a focus on identifying key differences and considerations between the three regimens to facilitate treatment decisions. 

Speakers: Jasmine Patel, PharmD, BCOP and Tashia Prince-Lacombe, MSN, AGNP-BC, Boston Medical Center